Huntleigh Advisors’s Adaptive Biotechnologies ADPT Stock Holding History
Bought
Maintained
Sold
Other funds holding ADPT
Huntleigh Advisors's ADPT Position: Q2 2026 in Review
Huntleigh Advisors increased its Adaptive Biotechnologies (ADPT) stake by 4.6% in Q2 2026, buying an estimated $62.5K and bringing the position to 93,171 shares worth $2M. The position accounts for 0.28% of the portfolio, ranked #88.
Huntleigh Advisors first reported a position in ADPT in Q3 2025 and has held it in 4 quarters since. 301 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.
- Huntleigh Advisors held 93,171 shares of Adaptive Biotechnologies worth $2M as of Q2 2026.
- Huntleigh Advisors bought 4,077 Adaptive Biotechnologies shares in Q2 2026, an estimated $62.5K.
- Adaptive Biotechnologies made up 0.28% of Huntleigh Advisors's portfolio in Q2 2026, its #88 holding.
- Huntleigh Advisors first reported a position in Adaptive Biotechnologies in Q3 2025 and has held it in 4 quarters since.
- 301 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.
Based on Huntleigh Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.